Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

S. J. Schraa; K. L. van Rooijen; D. E. W. van der Kruijssen; C. Rubio Alarcon; J. Phallen; M. Sausen; J. Simmons; V. M. H. Coupe; W. M. U. van Grevenstein; S. Elias; H. M. Verkooijen; M. M. Lacle; L. J. W. Bosch; D. van den Broek; G. A. Meijer; V. E. Velculescu; R. J. A. Fijneman; G. R. Vink; M. Koopman; Liselot van Iersel; PLCRC-MEDOCC group

doi:10.1186/s12885-020-07252-y

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

S. J. Schraa, K. L. van Rooijen, D. E. W. van der Kruijssen, C. Rubio Alarcon, J. Phallen, M. Sausen, J. Simmons, V. M. H. Coupe, W. M. U. van Grevenstein, S. Elias, H. M. Verkooijen, M. M. Lacle, L. J. W. Bosch, D. van den Broek, G. A. Meijer, V. E. Velculescu, R. J. A. Fijneman, G. R. Vink, M. Koopman^*, Liselot van IerselPLCRC-MEDOCC group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Web of Science)

Original language	English
Article number	790
Number of pages	10
Journal	BMC Cancer
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12885-020-07252-y
Publication status	Published - 20 Aug 2020

Keywords

Colon cancer
Circulating tumor DNA
ctDNA
Adjuvant chemotherapy
TwiCs
RANDOMIZED CONTROLLED-TRIAL
CELL-FREE DNA
COLORECTAL-CANCER
RESIDUAL DISEASE
FLUOROURACIL
RECURRENCE
SURVIVAL
LEUCOVORIN
RISK
OXALIPLATIN

Access to Document

10.1186/s12885-020-07252-yLicence: CC BY

Cite this

Schraa, S. J., van Rooijen, K. L., van der Kruijssen, D. E. W., Alarcon, C. R., Phallen, J., Sausen, M., Simmons, J., Coupe, V. M. H., van Grevenstein, W. M. U., Elias, S., Verkooijen, H. M., Lacle, M. M., Bosch, L. J. W., van den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J. A., Vink, G. R., Koopman, M., ... PLCRC-MEDOCC group (2020). Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer, 20(1), [790]. https://doi.org/10.1186/s12885-020-07252-y

Schraa, S. J. ; van Rooijen, K. L. ; van der Kruijssen, D. E. W. ; Alarcon, C. Rubio ; Phallen, J. ; Sausen, M. ; Simmons, J. ; Coupe, V. M. H. ; van Grevenstein, W. M. U. ; Elias, S. ; Verkooijen, H. M. ; Lacle, M. M. ; Bosch, L. J. W. ; van den Broek, D. ; Meijer, G. A. ; Velculescu, V. E. ; Fijneman, R. J. A. ; Vink, G. R. ; Koopman, M. ; van Iersel, Liselot ; PLCRC-MEDOCC group. / Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE) : study protocol for a trial within a cohort study. In: BMC Cancer. 2020 ; Vol. 20, No. 1.

@article{17d97cea5d294ad2b8c773c1135a40cc,

title = "Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study",

keywords = "Colon cancer, Circulating tumor DNA, ctDNA, Adjuvant chemotherapy, TwiCs, RANDOMIZED CONTROLLED-TRIAL, CELL-FREE DNA, COLORECTAL-CANCER, RESIDUAL DISEASE, FLUOROURACIL, RECURRENCE, SURVIVAL, LEUCOVORIN, RISK, OXALIPLATIN",

author = "Schraa, {S. J.} and {van Rooijen}, {K. L.} and {van der Kruijssen}, {D. E. W.} and Alarcon, {C. Rubio} and J. Phallen and M. Sausen and J. Simmons and Coupe, {V. M. H.} and {van Grevenstein}, {W. M. U.} and S. Elias and Verkooijen, {H. M.} and Lacle, {M. M.} and Bosch, {L. J. W.} and {van den Broek}, D. and Meijer, {G. A.} and Velculescu, {V. E.} and Fijneman, {R. J. A.} and Vink, {G. R.} and M. Koopman and {van Iersel}, Liselot and {PLCRC-MEDOCC group}",

year = "2020",

month = aug,

day = "20",

doi = "10.1186/s12885-020-07252-y",

language = "English",

volume = "20",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd",

number = "1",

}

Schraa, SJ, van Rooijen, KL, van der Kruijssen, DEW, Alarcon, CR, Phallen, J, Sausen, M, Simmons, J, Coupe, VMH, van Grevenstein, WMU, Elias, S, Verkooijen, HM, Lacle, MM, Bosch, LJW, van den Broek, D, Meijer, GA, Velculescu, VE, Fijneman, RJA, Vink, GR, Koopman, M , van Iersel, L & PLCRC-MEDOCC group 2020, 'Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study', BMC Cancer, vol. 20, no. 1, 790. https://doi.org/10.1186/s12885-020-07252-y

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE) : study protocol for a trial within a cohort study. / Schraa, S. J.; van Rooijen, K. L.; van der Kruijssen, D. E. W.; Alarcon, C. Rubio; Phallen, J.; Sausen, M.; Simmons, J.; Coupe, V. M. H.; van Grevenstein, W. M. U.; Elias, S.; Verkooijen, H. M.; Lacle, M. M.; Bosch, L. J. W.; van den Broek, D.; Meijer, G. A.; Velculescu, V. E.; Fijneman, R. J. A.; Vink, G. R.; Koopman, M.; van Iersel, Liselot; PLCRC-MEDOCC group.

In: BMC Cancer, Vol. 20, No. 1, 790, 20.08.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE)

T2 - study protocol for a trial within a cohort study

AU - Schraa, S. J.

AU - van Rooijen, K. L.

AU - van der Kruijssen, D. E. W.

AU - Alarcon, C. Rubio

AU - Phallen, J.

AU - Sausen, M.

AU - Simmons, J.

AU - Coupe, V. M. H.

AU - van Grevenstein, W. M. U.

AU - Elias, S.

AU - Verkooijen, H. M.

AU - Lacle, M. M.

AU - Bosch, L. J. W.

AU - van den Broek, D.

AU - Meijer, G. A.

AU - Velculescu, V. E.

AU - Fijneman, R. J. A.

AU - Vink, G. R.

AU - Koopman, M.

AU - van Iersel, Liselot

AU - PLCRC-MEDOCC group

PY - 2020/8/20

Y1 - 2020/8/20

KW - Colon cancer

KW - Circulating tumor DNA

KW - ctDNA

KW - Adjuvant chemotherapy

KW - TwiCs

KW - RANDOMIZED CONTROLLED-TRIAL

KW - CELL-FREE DNA

KW - COLORECTAL-CANCER

KW - RESIDUAL DISEASE

KW - FLUOROURACIL

KW - RECURRENCE

KW - SURVIVAL

KW - LEUCOVORIN

KW - RISK

KW - OXALIPLATIN

U2 - 10.1186/s12885-020-07252-y

DO - 10.1186/s12885-020-07252-y

M3 - Article

C2 - 32819390

VL - 20

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 790

ER -